Trial reportBritish journal of cancer2013
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
Trial report in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.Neurology · 2025Trial
- Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study.Annals of clinical and translational neurology · 2024Trial
- Clinical Investigation of Large Volume Subcutaneous Delivery up to 25 mL for Lean and Non-Lean Subjects.Pharmaceutical research · 2024Trial
- Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.British journal of haematology · 2020Trial
- Trial
- Harnessing Quantitative Medicine to Advance Oncology Drug Development.Clinical and translational science · 2026Review
- Transitioning Therapeutic Antibodies in Oncology from Intravenous to Hyaluronidase-Facilitated Subcutaneous Administration.Clinical pharmacokinetics · 2026Review
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- The Safety, Tolerability, and Pharmacokinetics of ALT-BB4 (A Novel Recombinant Hyaluronidase): A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study in Healthy Volunteers.Dermatology and therapy · 2025Article
- Hyaluronidase: structure, mechanism of action, diseases and therapeutic targets.Molecular biomedicine · 2025Review
- Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation.Bioconjugate chemistry · 2024Article
- Modeling the subcutaneous pharmacokinetics of antibodies co-administered with rHuPH20.Clinical and translational science · 2024Article
- Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies.Frontiers in immunology · 2024Article
- MPETDrug delivery · 2023Article
- Crystalline Antibody-Laden Alginate Particles: A Platform for Enabling High Concentration Subcutaneous Delivery of Antibodies.Advanced healthcare materials · 2023Article
- Mixed-dimensional multi-scale poroelastic modeling of adipose tissue for subcutaneous injection.Biomechanics and modeling in mechanobiology · 2022Article
- Article
- Alternative Routes of Administration for Therapeutic Antibodies-State of the Art.Antibodies (Basel, Switzerland) · 2022Review
- Discovering Novel Small Molecule Compound for Prevention of Monoclonal Antibody Self-Association.Antibodies (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRituximab and trastuzumab were the first therapeutic monoclonal antibodies (mAbs) approved in oncology. Both antibodies are delivered by the intravenous (IV) route, but recently subcutaneous (SC) formulations have been developed. Subcutaneous administration of mAbs can offer substantial patient and resource benefits compared with IV, but SC administration of some mAbs can be limited by drug volume. Recombinant human hyaluronidase (rHuPH20) temporarily degrades hyaluronan, allowing SC delivery of drug volumes that might not otherwise be feasible.
methodsClinical trials assessing coformulation of rituximab or trastuzumab with rHuPH20 for SC administration were reviewed.
resultsPhase I trials of rituximab SC maintenance therapy in patients with follicular lymphoma and trastuzumab SC in healthy volunteers and patients with early breast cancer have demonstrated substantially shorter administration times and comparable tolerability and pharmacokinetics compared with IV formulations. Rituximab SC 1400-mg and trastuzumab SC 600-mg doses were identified for further study. Phase III clinical data for rituximab SC 1400 mg have shown comparable efficacy to rituximab IV, and initial clinical data suggest comparable efficacy of trastuzumab SC 600 mg and the IV formulation.
conclusionCoformulation with rHuPH20 may enable effective, well-tolerated, cost-effective, and convenient SC administration of rituximab and trastuzumab. Additional studies are ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.